Research work · 2019

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony S.K. Mok, Yi-Long Lung Cancer Wu, Iveta Kudaba

The Lancet

Read free full text

DOI: 10.1016/s0140-6736(18)32409-7